Daratumumab Plus VTd Induction and Maintenance: Transforming Outcomes in Newly Diagnosed Multiple Myeloma—Long-Term MRD and PFS Insights from CASSIOPEIA

Highlights

• Daratumumab plus VTd (D-VTd) induction/consolidation and daratumumab maintenance consistently achieve the highest rates of minimal residual disease (MRD) negativity and progression-free survival (PFS) in newly diagnosed, transplant-eligible multiple myeloma.
• MRD negativity rates are improved at both 10^-5 and 10^-6 levels, regardless of cytogenetic risk or postinduction status, with daratumumab-based regimens.
• These benefits are maintained with a median follow-up of over 80 months, underscoring the long-term durability of deep responses.
• Daratumumab maintenance offers significant PFS advantages over observation, independent of prior induction/consolidation choice or MRD status post-consolidation.

Study Background and Disease Burden